Roche to take $1bn majority stake in Foundation Medicine
This article was originally published in Clinica
Roche is to take a majority stake in molecular information and genomic analysis firm Foundation Medicine (FMI) in a move that could see it invest up to $1.18bn.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.